International Journal of Endocrinology and Metabolism

Published by: Kowsar
Corrected Proof scheduled for 16 (3)

Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report

Shu Teng Chai 1 , * , Amalina Haydar Ali Tajuddin 1 , Norasyikin A. Wahab 1 , Norlaila Mustafa 1 , Norlela Sukor 1 and Nor Azmi Kamaruddin 1
Authors Information
1 The Diabetes and Endocrine Unit, Department of Medicine, National University of Malaysia Medical Centre, Kuala Lumpur, Malaysia
Article information
  • International Journal of Endocrinology and Metabolism: , In Press (In Press); e65233
  • Published Online: June 25, 2018
  • Article Type: Case Report
  • Received: January 3, 2018
  • Revised: April 26, 2018
  • Accepted: May 9, 2018
  • DOI: 10.5812/ijem.65233

To Cite: Teng Chai S, Haydar Ali Tajuddin A, A. Wahab N, Mustafa N, Sukor N, et al. Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report, Int J Endocrinol Metab. Online ahead of Print ;In Press(In Press):e65233. doi: 10.5812/ijem.65233.

Abstract
Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Introduction
2. Case Presentation
3. Discussion
Footnotes
References
  • 1. Malaysian Adverse Drug Reactions (MADRAC). Oral Ketoconazole: restriction of use to hospitals and tightening of indications. Malaysian Adverse Drug Reactions Newsletter; 2014.
  • 2. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-31. doi: 10.1210/jc.2015-1818. [PubMed: 26222757]. [PubMed Central: PMC4525003].
  • 3. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 2002;5(2):77-82. [PubMed: 12675504].
  • 4. Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623-30. doi: 10.1210/jc.2013-3628. [PubMed: 24471573].
  • 5. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984;86(3):503-13. [PubMed: 6319220].
  • 6. Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol. 1986;3(3):399-406. [PubMed: 3559147].
  • 7. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999;48(6):847-52. [PubMed: 10594489]. [PubMed Central: PMC2014312].
  • 8. British National Formulary (BNF). Ketoconazole. National Institute of Health and Care Excellence (NICE). 2017. Available from: https://bnf.nice.org.uk/drug/ketoconazole.html.
  • 9. Therapeutic Goods Administration (TGA). Oral ketoconazole (Nizoral) 200mg tablets. Department of Health, Australian Government; 2017. Available from: https://www.tga.gov.au/alert/oral-ketoconazolenizoral-200-mg-tablets.
  • 10. Hon-Yeung C. Deregistration of Oral Pharmaceutical Products Containing Ketoconazole. Hong Kong Pharm J. 2014;21(1):6.
  • 11. China Food and Drug Administration (CFDA). Ketoconazole. 2017. Available from: www.sfda.gov.cn/WS01/CL0087/122883.html.
  • 12. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. 2013.
  • 13. European Medicines Agency. Recommendation for maintenance of orphan designation at the time of marketing authorization: Ketoconazole HRA (ketoconazole) for the treatment of Cushing's syndrome. European Medicines Agency/Committee for Orphan Medicinal Products orphan designation recommendation. 2015. Available from: www.ema.europa.eu/docs/en_GB/document_library/Orphan_review/2015/01/WC500181644.pdf.
  • 14. United States Food and Drug Administration (U.S. FDA). FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2016. Available from: http://www.fda.gov/drugs/drugsafety/ucm362415.htm.
  • 15. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330(4):263-72. doi: 10.1056/NEJM199401273300407. [PubMed: 8272088].
  • 16. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154(4):519-24. doi: 10.1530/eje.1.02120. [PubMed: 16556713].
  • 17. van der Pas R, Hofland LJ, Hofland J, Taylor AE, Arlt W, Steenbergen J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403-12. doi: 10.1530/JOE-12-0310. [PubMed: 23038793].
  • 18. Burns K, Christie-David D, Gunton JE. Fluconazole in the treatment of Cushing's disease. Endocrinol Diabetes Metab Case Rep. 2016;2016:150115. doi: 10.1530/EDM-15-0115. [PubMed: 26858837]. [PubMed Central: PMC4744941].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments